Navigation Links
Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
Date:7/30/2013

EVANSTON, Ill., July 30, 2013 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced issuance of a new U.S. patent for its lead compound, GLYX-13. The new patent, which covers methods of treating major depressive disorder, expires in 2030. GLYX-13 has demonstrated good safety, robust efficacy and rapid onset of effect within hours of a single dose in a Phase II trial.

"Issuance of this new patent extending protection for GLYX-13 is an important development for Naurex and adds significant value to our depression program," noted CEO Derek Small. "In addition, we are continuing to pursue additional patents for GLYX-13 to further fortify our patent portfolio for this promising new drug."

GLYX-13 is a selective NMDA receptor partial agonist, a new class of central nervous system-active compounds discovered by Naurex scientists. It is currently being assessed in a 400-subject Phase Il repeated dose clinical trial. Results from the initial Phase II trial showed that a single administration of GLYX-13 produced statistically significant reductions in depression scores in subjects who had failed treatment with current antidepressants. The reductions were evident within 24 hours and persisted for an average of seven days. In clinical studies to date, GLYX-13 has been well tolerated and has not produced any of the schizophrenia-like effects associated with other drugs that modulate the NMDA receptor.

GLYX-13 was developed based on the work of company founder, Joseph R. Moskal, PhD, and his colleagues at the Falk Center for Molecular Therapeutics at Northwestern University.

U.S. Patent No. 8,492,340 B2 issued on July 23, 2013, is assigned to Northwestern University and exclusively licensed to Naurex Inc.

About Naurex
Naurex Inc. is a clinical-stage private company developing novel therapies to address unmet needs in psychiatry and neurology based on a new mechanism of action for modulating the NMDA receptor (NMDAR). Lead product GLYX-13 has shown promising antidepressant activity with excellent safety in a Phase Ila clinical trial in subjects who had failed treatment with existing agents. GLYX-13 is currently in a Phase IIb repeated dose clinical trial as adjunctive therapy for major depressive disorder. Oral and IV formulations of Naurex's 2nd-generation compound, NRX-1074, are currently in Phase I clinical studies.  Naurex's patented novel chemistry classes represent a platform for the discovery and development of new CNS therapies and have generated a robust pipeline that includes 3rd- and 4th-generation NMDAR subtype-selective partial agonists with preclinical proof of concept in a number of CNS disorders. For more information, visit www.naurex.com.Contacts:

MediaNaurex Inc.

BLL Partners, LLCAshish Khanna

Barbara LindheimVice President, Corporate Development

(212) 584-2276(847) 871-0377

blindheim@bllbiopartners.comcorporate@naurex.com
'/>"/>

SOURCE Naurex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
2. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
3. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
4. Misonix Announces New Distribution Agreement For Panama
5. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
6. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
7. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
8. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
9. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. STAAR Surgical Announces First Quarter 2012 Results Release Date and Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
Breaking Medicine News(10 mins):